XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues:    
Revenues $ 42,010,949 $ 35,985,043
Costs and expenses:    
Cost of products sold 9,118,521 8,811,248
Selling and marketing 16,660,945 15,015,424
Research and development 6,688,924 5,684,465
General and administrative 10,180,120 9,780,026
Amortization 5,067,368 4,371,300
Total costs and expenses 47,715,878 43,662,463
Operating income (loss) (5,704,929) (7,677,420)
Interest income 98,405 26,081
Other Income 0 2,187,140
Other income - gain on insurance proceeds 611,330 0
Interest expense (585,995) (98,031)
Net income (loss) from continuing operations (5,581,189) (5,562,230)
Income tax (expense) benefit (68,850) (34,891)
Net income (loss) from continuing operations (5,650,039) (5,597,121)
Discontinued operations net of tax 0 1,994,322
Net income (loss) (5,650,039) (3,602,799)
Net loss at subsidiary attributable to noncontrolling interests 79,798 95,212
Net income (loss) attributable to common shareholders $ (5,570,241) $ (3,507,587)
Earnings (loss) per share attributable to common shareholders:    
-Continuing operations-basic $ (0.38) $ (0.37)
-Discontinued operations-basic 0 0.13
Basic (in USD per share) (0.38) (0.24)
-Continuing operations-diluted (0.38) (0.37)
-Discontinued operations-diluted 0 0.13
Diluted (in USD per share) $ (0.38) $ (0.24)
Weighted-average common shares outstanding:    
Basic (in shares) 14,563,592 14,904,834
Diluted (in shares) 14,563,592 14,904,834
Product    
Revenues:    
Revenues $ 40,681,182 $ 35,045,259
Other    
Revenues:    
Revenues $ 1,329,767 $ 939,784